L Barrelet
About
In The Last Decade
L Barrelet
15 papers receiving 354 citations
Peers
Comparison fields: 5 of 55
- Oncology 202
- Immunology 147
- Cancer Research 93
- Genetics 80
- Molecular Biology 79
Countries citing papers authored by L Barrelet
This map shows the geographic impact of L Barrelet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L Barrelet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L Barrelet more than expected).
Fields of papers citing papers by L Barrelet
This network shows the impact of papers produced by L Barrelet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L Barrelet. The network helps show where L Barrelet may publish in the future.
Co-authorship network of co-authors of L Barrelet
This figure shows the co-authorship network connecting the top 25 collaborators of L Barrelet. A scholar is included among the top collaborators of L Barrelet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L Barrelet. L Barrelet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 5 | |
| 2 | [Palliative care: therapeutic possibilities for patients at the end of life]. | 1 |
| 3 | Preferential clonogenic deficit of CD8-positive T-lymphocytes infiltrating human solid tumors. | 81 |
| 4 | 80 | |
| 5 | Combination of mitomycin, vindesine, and cisplatin in the treatment of head and neck squamous cell carcinoma. | 3 |
| 6 | 126 | |
| 7 | 10 | |
| 8 | Combination chemotherapy for non-small cell lung cancer with doxorubicin and mitomycin or cisplatin and etoposide. | 23 |
| 9 | 13 | |
| 10 | 13 | |
| 11 | [Circulating antibody complexes and cancer]. | 4 |
| 12 | Microbiological relevance and clinical potential of ampicillin-cloxacillin synergism. | 3 |
| 13 | [Palliative treatment of metastatic breast cancer with diethyldioxystilbene diphosphate (Honvan)]. | 1 |
| 14 | 4 | |
| 15 | 6 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.